14 June 2020

• An editorial warns that OWS is underfunded; an additional US $16 billion is needed to achieve its goal and allow the purchase of a year’s supply of existing vaccines, which would create space for future vaccine production and supply. Furthermore, global shortages of vials and syringes could delay vaccine delivery. Source
• Sinovac announces favorable preliminary results from its phase II trial of CoronaVac, saying that it induced neutralizing antibodies in more than 90% of study participants tested 14 days after getting two injections, two weeks apart, although it is not known whether these will prevent COVID-19. Source
• The EU Inclusive Vaccines Alliance (IVA) makes an advanced purchase deal with AstraZeneca for up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with delivery anticipated by the end of 2020. Source

Return to the timeline